MARKET

SYRS

SYRS

Syros Pharmaceut
NASDAQ
6.64
+0.70
+11.78%
After Hours: 6.43 -0.21 -3.16% 19:55 10/04 EDT
OPEN
6.26
PREV CLOSE
5.94
HIGH
6.81
LOW
6.16
VOLUME
218.56K
TURNOVER
0
52 WEEK HIGH
48.00
52 WEEK LOW
5.25
MARKET CAP
41.83M
P/E (TTM)
-0.3836
1D
5D
1M
3M
1Y
5Y
Insider Buy: Syros Pharmaceuticals
Insider Buy: Syros Pharmaceuticals
MT Newswires · 1d ago
GLSI, APRN: The Top 5 Short Squeeze Stocks to Watch This Week
Investor Place · 1d ago
Grenwich LilfeSciences, Blue Apron And 3 More Short Squeeze Candidates That May Soar
Potential short squeeze plays gained steam in 2021 and have continued through 2022 with new traders looking for the next huge move. Here’s a look at the top five short squeeze candidates for the week of Oct. 3 based on the Fintel short squeeze leaderboard.
Benzinga · 1d ago
10 Short Squeeze Candidates That May Soar: Minerva Neurosciences, FaZe, Getty Images And More
Potential short squeeze plays gained steam in 2021 and have continued through 2022 with new traders looking for the next huge move.
Benzinga · 09/26 14:48
Syros Pharmaceuticals, Inc. (SYRS) Upgraded to Buy: What Does It Mean for the Stock?
Syros Pharmaceuticals, Inc. (SYRS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Zacks · 09/23 16:00
SYRS, FREY and HKD are among pre market gainers
AMTD Digital (HKD) +12%. Syros Pharmaceuticals (<a href="https://seeki...
Seekingalpha · 09/21 12:12
Avidity Partners Reports In 13G Filing 9.9% Passive Stake In Syros Pharmaceuticals As Of Sept. 16
-SEC Filing
Benzinga · 09/20 20:42
BRIEF-Avidity Partners Management Reports 9.9% Passive Stake In Syros Pharmaceuticals As Of Sept 16
BRIEF-Avidity Partners Management Reports 9.9% Passive Stake In Syros Pharmaceuticals As Of Sept 16
Reuters · 09/20 20:40
More
About SYRS
Syros Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on redefending the power of small molecules to control the expression of genes. The Company is engaged in developing treatments for cancer and diseases resulting from mutations of a single gene, also known as monogenic diseases, and building a clinical-stage pipeline of gene control medicine. The Company's lead product candidates include Tamibarotene, SY-2101 and SY-5609. Its Tamibarotene, is a selective retinoic acid receptor alpha (RARα), agonist RARA-positive patients with higher-risk myelodysplastic syndrome (HR-MDS) and acute myeloid leukemia (AML). Its SY-2101, is an oral form of arsenic trioxide (ATO) being developed for the treatment of acute promyelocytic leukemia (APL). Its SY-5609, is a selective and potent oral inhibitor of cyclin-dependent kinase 7 (CDK7) which is being development for patients with select solid tumors and blood cancers.

Webull offers kinds of Syros Pharmaceuticals Inc stock information, including NASDAQ:SYRS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SYRS stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading SYRS stock methods without spending real money on the virtual paper trading platform.